These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 35950629)

  • 21. Genomic and Phenotypic Evolution of Tigecycline-Resistant Acinetobacter baumannii in Critically Ill Patients.
    Zhang J; Xie J; Li H; Wang Z; Yin Y; Wang S; Chen H; Wang Q; Wang H
    Microbiol Spectr; 2022 Feb; 10(1):e0159321. PubMed ID: 35044218
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical implications of glycoproteomics for Acinetobacter baumannii.
    Kinsella RL; Scott NE; Feldman MF
    Expert Rev Proteomics; 2015 Feb; 12(1):1-3. PubMed ID: 25496064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association of capsular polysaccharide locus 2 with prognosis of
    Yang JL; Yang CJ; Chuang YC; Sheng WH; Chen YC; Chang SC
    Emerg Microbes Infect; 2022 Dec; 11(1):83-90. PubMed ID: 34825848
    [No Abstract]   [Full Text] [Related]  

  • 24. Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection.
    Ainsworth S; Ketter PM; Yu JJ; Grimm RC; May HC; Cap AP; Chambers JP; Guentzel MN; Arulanandam BP
    Vaccine; 2017 Jun; 35(26):3387-3394. PubMed ID: 28522011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunogenic reactivity of recombinant PKF and AbOmpA proteins as serum resistance factors against sepsis of Acinetobacter baumannii.
    Bolourchi N; Shahcheraghi F; Shirazi AS; Janani A; Bahrami F; Badmasti F
    Microb Pathog; 2019 Jun; 131():9-14. PubMed ID: 30930220
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bioinformatics analysis and epitope screening of a potential vaccine antigen TolB from Acinetobacter baumannii outer membrane protein.
    Song X; Zhang H; Zhang D; Xie W; Zhao G
    Infect Genet Evol; 2018 Aug; 62():73-79. PubMed ID: 29673984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the trimeric autotransporter Ata as a vaccine candidate against Acinetobacter baumannii infections.
    Bentancor LV; Routray A; Bozkurt-Guzel C; Camacho-Peiro A; Pier GB; Maira-Litrán T
    Infect Immun; 2012 Oct; 80(10):3381-8. PubMed ID: 22825448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combating tigecycline resistant Acinetobacter baumannii: A leap forward towards multi-epitope based vaccine discovery.
    Ahmad S; Ranaghan KE; Azam SS
    Eur J Pharm Sci; 2019 Apr; 132():1-17. PubMed ID: 30797936
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Investigation of the virulence factors of multidrug-resistant Acinetobacter baumannii isolates].
    Eraç B; Yılmaz FF; Hoşgör Limoncu M; Oztürk I; Aydemir S
    Mikrobiyol Bul; 2014 Jan; 48(1):70-81. PubMed ID: 24506717
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical Synthesis and Antigenic Evaluation of Inner Core Oligosaccharides from Acinetobacter baumannii Lipopolysaccharide.
    Zhou XY; Li LX; Zhang Z; Duan SC; Huang YW; Luo YY; Mu XD; Chen ZW; Qin Y; Hu J; Yin J; Yang JS
    Angew Chem Int Ed Engl; 2022 Jul; 61(29):e202204420. PubMed ID: 35543248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization.
    Russo TA; Beanan JM; Olson R; MacDonald U; Cox AD; St Michael F; Vinogradov EV; Spellberg B; Luke-Marshall NR; Campagnari AA
    Infect Immun; 2013 Mar; 81(3):915-22. PubMed ID: 23297385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anti-Omp34 antibodies protect against Acinetobacter baumannii in a murine sepsis model.
    Naghipour Erami A; Rasooli I; Jahangiri A; Darvish Alipour Astaneh S
    Microb Pathog; 2021 Dec; 161(Pt B):105291. PubMed ID: 34798280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. OmpW is a potential target for eliciting protective immunity against Acinetobacter baumannii infections.
    Huang W; Wang S; Yao Y; Xia Y; Yang X; Long Q; Sun W; Liu C; Li Y; Ma Y
    Vaccine; 2015 Aug; 33(36):4479-85. PubMed ID: 26207591
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunoprotective potential of in silico predicted Acinetobacter baumannii outer membrane nuclease, NucAb.
    Garg N; Singh R; Shukla G; Capalash N; Sharma P
    Int J Med Microbiol; 2016 Jan; 306(1):1-9. PubMed ID: 26614015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vivo antibacterial activity of Zataria multiflora Boiss extract and its components, carvacrol, and thymol, against colistin-resistant Acinetobacter baumannii in a pneumonic BALB/c mouse model.
    Hassannejad N; Bahador A; Rudbari NH; Modarressi MH; Parivar K
    J Cell Biochem; 2019 Nov; 120(11):18640-18649. PubMed ID: 31338900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sequential Linkage of Carbohydrate Antigens to Mimic Capsular Polysaccharides: Toward Semisynthetic Glycoconjugate Vaccine Candidates against
    Seco BMS; Xu FF; Grafmüller A; Kottari N; Pereira CL; Seeberger PH
    ACS Chem Biol; 2020 Sep; 15(9):2395-2405. PubMed ID: 32835479
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A Streptococcus pneumoniae Type 2 Oligosaccharide Glycoconjugate Elicits Opsonic Antibodies and Is Protective in an Animal Model of Invasive Pneumococcal Disease.
    Emmadi M; Khan N; Lykke L; Reppe K; G Parameswarappa S; Lisboa MP; Wienhold SM; Witzenrath M; Pereira CL; Seeberger PH
    J Am Chem Soc; 2017 Oct; 139(41):14783-14791. PubMed ID: 28945368
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comprehensive review on potential therapeutic inhibitors of nosocomial Acinetobacter baumannii superbugs.
    Srikanth D; Joshi SV; Ghouse Shaik M; Pawar G; Bujji S; Kanchupalli V; Chopra S; Nanduri S
    Bioorg Chem; 2022 Jul; 124():105849. PubMed ID: 35594766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recombinant N-terminal outer membrane porin (OprF) of Pseudomonas aeruginosa is a promising vaccine candidate against both P. aeruginosa and some strains of Acinetobacter baumannii.
    Bahey-El-Din M; Mohamed SA; Sheweita SA; Haroun M; Zaghloul TI
    Int J Med Microbiol; 2020 Apr; 310(3):151415. PubMed ID: 32156509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antibiotic modulation of capsular exopolysaccharide and virulence in Acinetobacter baumannii.
    Geisinger E; Isberg RR
    PLoS Pathog; 2015 Feb; 11(2):e1004691. PubMed ID: 25679516
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.